MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 40 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

venueno affno abstractunlabeled
10.1016/s1541-9800(10)70140-x
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
venueno affno abstractunlabeled
10.1016/s1541-9800(07)70431-3
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
affno abstractunlabeled
43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong +4 more
2023· article· en· Journal of the American Academy of Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affno abstractunlabeled
10.1016/j.yspm.2012.09.014
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
venueno affno abstractunlabeled
10.1016/j.abdp.2024.07.031
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
venueno affno abstractunlabeled
10.1016/j.abdp.2019.04.005
María Laura Galimberti, Aldana Soledad Vacas, Bárbara Aguilar Hernández, María Luz Bollea Garlatti, María Julia Cura, Ricardo Galimberti
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
fundno affno abstractunlabeled
AB0887 Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
A. Ogdie, J. F. Merola, P. J. Mease, Christopher T. Ritchlin, Jessica Scher, D. Chan +6 more
2022· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affno abstractunlabeled
10.1016/s1541-9800(07)70372-1
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
affno abstractunlabeled
Psoriasis
Rebecca M. Law, Erin Bartholomew, Mimi Chung, Marwa Hakimi, Samuel Yeroushalmi, Wilson Liao
2025· book-chapter· en· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Ixekizumab dans le traitement du psoriasis en plaques modéré à sévère : résultats à 60 semaines d’une étude de phase 3, en double aveugle, avec une phase d’induction suivie d’une phase de re-randomisation (UNCOVER-1)
Kenneth B. Gordon, Andrew Blauvelt, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, G. Cameron +9 more
2015· article· fr· Annales de Dermatologie et de Vénéréologie· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
venueno affno abstractunlabeled
10.1016/s1541-9800(08)70631-8
2000· article· en· Time to knit· Immunology and Microbiology
machine prediction:candidate · insufficient_payloadconsensus · insufficient_payload
0
citations
aboutno affunlabeled
Ustekinumab in the treatment of psoriasis
Marina Talamonti, Marco Galluzzo, Sergio Chimenti
2015· article· en· Journal of symptoms and signs· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
← previousnext →

How this was built: Screen · Findings · About